| Treatment | Category | Mechanism of Action | Efficacy (tremor reduction %) | Key Side Effects | Evidence Level |
|---|---|---|---|---|---|
| Propranolol | First-line | Nonselective β-adrenergic blocker; reduces peripheral and possibly central tremor oscillation/amplitude | ~50–70% tremor amplitude reduction in responders; most commonly used oral therapy (pqac-00000020, pqac-00000047) | Bradycardia, hypotension, fatigue; contraindicated in asthma/COPD; long-term discontinuation common (pqac-00000020, pqac-00000046) | Guideline-supported standard therapy; RCT/meta-analysis and real-world evidence (pqac-00000020, pqac-00000021, pqac-00000046) |
| Primidone | First-line | Barbiturate-related antiseizure drug; enhances GABAergic inhibition via phenobarbital metabolite and related effects | ~50–70% tremor amplitude reduction in responders (pqac-00000020) | Sedation, dizziness, nausea, ataxia; tolerability limits adherence (pqac-00000020, pqac-00000023) | Guideline-supported standard therapy; RCT/meta-analysis evidence (pqac-00000020, pqac-00000021) |
| Topiramate | Second-line | Antiseizure drug; multimodal action including sodium channel effects and enhancement of GABAergic tone | Variable; beneficial in some RCTs, but less consistent than first-line agents (pqac-00000020, pqac-00000021) | Cognitive slowing, paresthesia, weight loss, fatigue | Moderate evidence from RCTs/network meta-analysis; off-label (pqac-00000021) |
| Gabapentin | Second-line | Modulates α2δ calcium channel subunits; reduces excitatory neurotransmission | Variable/modest benefit in some trials; inconsistent overall (pqac-00000020, pqac-00000021) | Somnolence, dizziness, edema, imbalance | Moderate-to-low evidence; off-label, mixed trial results (pqac-00000020, pqac-00000021) |
| Alprazolam | Second-line | Benzodiazepine; positive allosteric modulator of GABA-A receptors | Variable symptomatic benefit in some patients (pqac-00000020, pqac-00000021) | Sedation, dependence, falls, cognitive impairment | Limited-to-moderate evidence; off-label, usually adjunctive (pqac-00000020, pqac-00000021) |
| Botulinum toxin / incobotulinumtoxinA | Second-line / Focal refractory | Presynaptic blockade of acetylcholine release at neuromuscular junction; weakens tremulous muscles | Helpful particularly for hand, head, or voice tremor; magnitude varies by target muscle and study (pqac-00000021, pqac-00000023) | Focal weakness, dysphagia/voice weakness depending on injection site | Moderate evidence from controlled studies; useful in selected refractory cases (pqac-00000020, pqac-00000021) |
| Deep brain stimulation (VIM-DBS) | Surgical | High-frequency modulation of ventral intermediate thalamic nucleus within cerebello-thalamo-cortical circuit | Unilateral: ~53.4–62.8% at 12 months; bilateral: ~66–78% with better axial/voice tremor control (pqac-00000022) | Dysarthria, gait imbalance, paresthesia, hardware/infection risks, stimulation-related adverse effects | High evidence for medication-refractory ET; established neurosurgical standard (pqac-00000020, pqac-00000022) |
| MRI-guided focused ultrasound thalamotomy (MRgFUS) | Surgical | Incisionless thermal lesioning of VIM thalamus | In bilateral staged series, ~59.98% reduction in CRST A+B at 6 months after second procedure; marked QoL improvement (pqac-00000022) | Gait instability, paresthesia, imbalance; usually mild-to-moderate in recent series (pqac-00000022) | High/moderate evidence; established option for medication-refractory ET (pqac-00000020, pqac-00000022) |
| Gamma Knife thalamotomy | Surgical / Experimental | Radiosurgical lesioning of contralateral VIM thalamus | Efficacy under active study; bilateral trial uses QUEST change at 12 months as primary endpoint (pqac-00000062) | Numbness, dysgeusia, gait/speech adverse effects under surveillance (pqac-00000062) | Ongoing Phase II/III prospective trial (NCT04748640) (pqac-00000062) |
| SAGE-324 / BIIB124 | Experimental | Neuroactive steroid positive allosteric modulator of GABA-A receptors | Phase 2 study in 67 patients reported significant tremor reduction (pqac-00000022) | Notable adverse effects; dose reductions required in 62% of participants (pqac-00000022) | Mid-stage clinical evidence; experimental (pqac-00000022) |
| BP1.4979 | Experimental | Selective dopamine D3 partial agonist | Efficacy unknown; current trial assesses change in TETRAS-P after 4 weeks (pqac-00000063) | Safety/tolerability under study; no definitive profile yet in ET (pqac-00000063) | Recruiting Phase II randomized placebo-controlled trial, NCT07074002 (pqac-00000063) |
| AGN-151607-DP (gemibotulinumtoxinA) | Experimental | Intramuscular botulinum toxin type A formulation for upper-limb tremor | Efficacy unknown; trial measures change from baseline in TETRAS/TETRAS-UL over 72 weeks (pqac-00000064) | Botulinum toxin-related weakness and injection-related adverse events are key concerns; safety endpoint included (pqac-00000064) | Recruiting Phase IIb randomized placebo-controlled trial, NCT07673107 (pqac-00000064) |
| Transcutaneous afferent patterned stimulation (TAPS) | Experimental / Device-based | Peripheral nerve stimulation intended to modulate tremor networks through patterned afferent input | Promising symptomatic tremor reduction with minimal side effects; exact effect size varies by study (pqac-00000020, pqac-00000023) | Skin irritation/discomfort, variable response | Regulatory-cleared device approach with emerging clinical evidence (pqac-00000020, pqac-00000021) |
| α6-GABAA modulators | Experimental / Preclinical | Positive modulation of cerebellar α6-containing extrasynaptic GABA-A receptors, especially on granule cells | Strong anti-tremor effects in harmaline models; human efficacy not yet established (pqac-00000038, pqac-00000040) | Preclinical focus on improved tolerability versus nonselective GABAergic drugs; human AE profile unknown | Preclinical animal-model evidence; mechanistically compelling but not established clinically (pqac-00000038, pqac-00000040, pqac-00000071) |


*Table: This table summarizes established, surgical, and investigational therapies for essential tremor, including mechanisms, approximate efficacy where reported, adverse effects, and current evidence level. It is useful for comparing standard-of-care options with newer agents and device-based interventions in development.*